Birth Control Litigation: Key Cases and Claims
Uncovering the major lawsuits against birth control manufacturers for defective products, hidden risks, and severe injuries faced by users.
Contraceptive products have empowered millions with reproductive choices, but certain devices and medications have led to devastating health complications, sparking waves of product liability lawsuits. These cases often allege failure to warn about risks, defective design, and aggressive marketing that downplayed dangers. From intrauterine devices fracturing inside bodies to injections linked to brain tumors, affected women have pursued compensation through individual suits, class actions, and multidistrict litigations (MDLs).
Historical Precedents in Contraceptive Defect Cases
The landscape of birth control litigation traces back decades, with early cases setting critical benchmarks for manufacturer accountability. One landmark involved the Dalkon Shield IUD, marketed in the 1970s by A.H. Robins Company. This device’s flawed design permitted bacterial ascension into the uterus, triggering pelvic inflammatory disease (PID), infertility, and ectopic pregnancies in thousands of users. The ensuing legal battles forced the company into bankruptcy, compensating over 9,000 claimants and establishing standards for proving causation in mass torts.
Similar patterns emerged with Norplant, a sub-dermal implant launched in the 1990s. Users reported intractable pain during removal, irregular bleeding, and psychological distress. By 1999, the manufacturer settled with 36,000 women, highlighting issues in long-acting reversible contraceptives (LARCs) where insertion and extraction complications amplify risks.
Current Waves of IUD-Related Product Liability Suits
Intrauterine devices remain focal points of contemporary litigation due to migration, embedding, and fragmentation risks. Paragard, a copper-based non-hormonal IUD, faces over 3,900 pending cases in an MDL as of late 2025. Plaintiffs claim the device breaks during removal, leaving fragments that necessitate invasive surgeries. A bellwether trial in Atlanta acquitted manufacturer Teva Pharmaceuticals, but the litigation persists, with women alleging inadequate warnings about breakage propensity.
Historically, Mirena IUD lawsuits accused Bayer of minimizing risks of uterine perforation and embedment. Though many settled confidentially, these cases underscored the need for robust post-market surveillance by the FDA.
The Future of AI: Preventing a Big Tech Monopoly >
| Device | Key Allegations | MDL Status (2025) | Notable Outcomes |
|---|---|---|---|
| Paragard | Breakage, embedding | 3,926 cases | Bellwether win for defendant |
| Mirena | Perforation, migration | Resolved | Multi-billion settlements |
| Essure | Pain, organ damage | Settled | $1.6B Bayer payout (2022) |
Depo-Provera: Emerging Brain Tumor Litigation
Depo-Provera, a progestin-only injectable contraceptive administered every three months, has surged in lawsuits over links to intracranial meningiomas—benign tumors fueled by progesterone. As of September 2025, the federal MDL boasts 806 cases, with over 1,000 total filings including state courts. Women assert Pfizer failed to disclose this risk despite international warnings, such as the UK’s 2024 mandate for tumor risk labeling.
Court filings detail plaintiffs undergoing craniotomies, experiencing vision loss, and facing lifelong neurological deficits. A June 2025 order streamlined MDL entry, allowing state case transfers. Momentum builds, mirroring past hormonal contraceptive battles, with experts citing studies showing dose-dependent tumor risk after prolonged use.
- Tumor Incidence: Meningiomas detected via MRI in long-term users.
- Causation Claims: Elevated progesterone receptors in tumors allegedly triggered by Depo-Provera.
- Compensation Sought: Medical bills, lost wages, pain and suffering.
Hormonal Contraceptives and Cardiovascular Risks
Oral contraceptives like Yaz and Yasmin (drospirenone-based) drew intense scrutiny for heightened venous thromboembolism (VTE) risks. Bayer settled 4,000+ claims for $1.69 billion by 2014, after evidence showed third-generation progestins doubled clot odds compared to earlier pills. NuvaRing vaginal rings faced parallel suits, with Merck paying $56 million amid stroke and heart attack reports.
These cases pivoted on “failure to warn,” as labels initially omitted comparative risks. FDA-mandated updates followed, but litigation revealed internal documents suggesting manufacturers prioritized sales over safety.
Permanent Sterilization Devices: Essure’s Legacy
Essure, Bayer’s hysteroscopic implant for tubal occlusion, promised non-incisional sterilization but delivered chronic pelvic pain, allergic reactions to nickel coils, and unintended migrations perforating organs. Post-2013 market entry, FDA adverse events topped 26,000 by 2018, prompting U.S. withdrawal. Bayer’s $1.6 billion settlement in 2022 resolved 90% of 39,000 claims, averaging $55,000 per plaintiff after fees.
Implanon/Nexplanon implants echoed woes: migration, ectopic pregnancies, and nerve damage. Over 100 lawsuits persist, emphasizing informed consent gaps in minor procedures.
Legal Foundations and Avenues for Claims
Birth control suits typically invoke strict product liability (defective design/manufacturing), negligence, breach of warranty, and fraud. Multidistrict litigation consolidates cases for efficiency, selecting bellwethers to gauge settlement viability. Success hinges on medical records proving device use, injury timing, and causation via expert testimony.
Statutes of limitations vary (1-4 years from discovery), urging prompt action. No-fault compensation funds are absent in the U.S., unlike some nations, leaving courts as primary recourse.
Product liability law holds manufacturers responsible regardless of care taken, prioritizing consumer safety in prescription medical products.
Patient Rights, FDA Oversight, and Future Trends
The FDA’s 510(k) clearance for devices like IUDs allows market entry via substantial equivalence to predicates, often bypassing rigorous trials—a critique in Essure and Paragard suits. Post-approval MAUDE database logs complaints, informing recalls. As of 2026, ongoing MDLs signal heightened scrutiny of LARCs and injectables.
Women harmed deserve representation from mass tort specialists. Free consultations assess eligibility, with contingency fees aligning incentives.
Frequently Asked Questions
What qualifies for a birth control lawsuit?
Serious injuries like organ perforation, tumors, clots, or device failure linked to inadequate warnings or defects. Consult an attorney for case review.
Which products face active MDLs in 2026?
Paragard ( breakage claims) and Depo-Provera (meningioma links), with thousands of docketed suits.
Are settlements guaranteed?
No, but historical payouts exceed billions. Bellwether results influence global resolutions.
How long do these cases take?
MDLs span 2-5 years; settlements accelerate post-discovery.
Can state cases join federal MDLs?
Yes, via court orders facilitating transfers for streamlined handling.
References
- Birth Control Lawsuits — Rouda Feder Tietjen & McGuinn. 2016-04. https://www.rftmlaw.com/blog/2016/april/birth-control-lawsuits/
- Birth Control Lawsuit [2026 Guide] — Robert King Law Firm. 2025. https://www.robertkinglawfirm.com/mass-torts/birth-control-lawsuit/
- Court Cases – Birth Control — American Civil Liberties Union. Accessed 2026. https://www.aclu.org/court-cases?issue=birth-control
- Depo-Provera Lawsuit Settlements 2024 — Anapol Weiss. 2024. https://www.anapolweiss.com/blog/depo-provera-lawsuit-settlements-2024-most-recent-in-a-long-line-of-litigation-against-unsafe-birth-control-products/
- The Risks of Long-Term Contraceptive Use & Your Legal Options — Kisling, Nestico & Redick. Accessed 2026. https://www.knrlegal.com/contraceptive-risks-legal-options/
Similar Articles
Read full bio of medha deb
